IPM Take
Women with epilepsy routinely receive conflicting messages at the point where neurology and motherhood meet. Take the medicine because seizures during the postpartum period can be dangerous, but worry that medicine may reach the infant through breast milk.
The MONEAD evidence helps reduce that false choice. At six years, breastfeeding during treatment with contemporary antiseizure medicines was not associated with adverse neurodevelopmental outcomes. The findings support existing recommendations for breastfeeding rather than routine avoidance.
Executive Summary
The prospective MONEAD cohort examined children born to women with epilepsy who used contemporary antiseizure medication regimens, including commonly used agents such as lamotrigine and levetiracetam.
At age six, children exposed to antiseizure medicines through breast milk did not show worse neurodevelopmental outcomes than children who were not breastfed under those exposures. Longer breastfeeding was associated with favourable adaptive behavioural outcomes in the study.
As an observational cohort, the study cannot eliminate all residual confounding or establish that breastfeeding itself caused better outcomes. Its importance lies in the absence of the adverse developmental signal that patients have often feared.
Why it matters
- Postpartum seizure control matters for the mother and the infant. Abrupt medication changes can create real neurological risk, while unnecessarily discouraging breastfeeding removes well-established maternal and infant benefits.
- The policy need is straightforward: neurology, obstetrics and paediatrics should deliver one coherent counselling pathway rather than leaving women to reconcile contradictory advice.
For women with epilepsy, pregnancy and breastfeeding turn ordinary treatment decisions into risk calculations.
Stopping medication may increase seizure risk. Continuing medication raises understandable questions about fetal or infant exposure. When evidence is weak, fear often fills the space, and women can be advised to avoid breastfeeding even when the actual risk is uncertain.
The new MONEAD follow-up provides valuable long-term reassurance. Children were assessed at six years, well beyond the short developmental windows that dominate many medication-safety studies. Exposure to contemporary antiseizure medicines through breastfeeding was not associated with worse neurodevelopmental outcomes.
That should change the tone of counselling.
The right message is not that every antiseizure medicine is interchangeable or that breastfeeding decisions require no individual assessment. Medication type, dose, maternal seizure control and infant health still matter. The point is that epilepsy treatment itself should no longer be treated as a reason to default away from breastfeeding.
This is a small but important example of personalised neurology becoming more humane. The objective is not simply to keep seizures controlled. It is to support a woman’s neurological health without unnecessarily narrowing the rest of her life.
